Summary TargeGen, Inc. (TargeGen) is a biopharmaceutical company. It develops small molecule kinase inhibitors to treat certain forms of lymphoma, leukemia and other hematological malignancies and blood disorders. The company’s principal product candidate, TG101348, is being developed by Sanofi for the treatment of patients afflicted with myeloproliferative diseases, apart from primary and secondary myelofibrosis (MF) and polycythemia vera (PV). It also has other tyrosine kinases in pre-clinical development. In July 2010, Sanofi completed 100% acquisition of the share capital of TargeGen. TargeGen received an upfront payment of $75m and will receive future milestone payments of up to $560m based on the success of its small molecule kinase inhibitors in the treatment of leukemia, lymphoma and other blood diseases. Subsequent to its acquisition, TargeGen has become a wholly-owned subsidiary of Sanofi. TargeGen is headquartered in San Diego, California, the US. TargeGen, Inc. - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information... Research Beam Model: Research Beam Product ID: 121024 250 USD New
TargeGen, Inc. - Pharmaceuticals & Healthcare - Deals and Alliances Profile
 
 

TargeGen, Inc. - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • Category : Pharmaceuticals
  • Published On : April   2014
  • Pages : 20
  • Publisher : GlobalData
 
 
 
Summary

TargeGen, Inc. (TargeGen) is a biopharmaceutical company. It develops small molecule kinase inhibitors to treat certain forms of lymphoma, leukemia and other hematological malignancies and blood disorders. The company’s principal product candidate, TG101348, is being developed by Sanofi for the treatment of patients afflicted with myeloproliferative diseases, apart from primary and secondary myelofibrosis (MF) and polycythemia vera (PV). It also has other tyrosine kinases in pre-clinical development. In July 2010, Sanofi completed 100% acquisition of the share capital of TargeGen. TargeGen received an upfront payment of $75m and will receive future milestone payments of up to $560m based on the success of its small molecule kinase inhibitors in the treatment of leukemia, lymphoma and other blood diseases. Subsequent to its acquisition, TargeGen has become a wholly-owned subsidiary of Sanofi. TargeGen is headquartered in San Diego, California, the US.

TargeGen, Inc. - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

Table Of Contents
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 3
TargeGen, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2008 to YTD 2014 4
TargeGen, Inc., Pharmaceuticals & Healthcare Deals By Type, 2008 to YTD 2014 5
TargeGen, Inc., Pharmaceuticals & Healthcare, Deals By Region, 2008 to YTD 2014 6
TargeGen, Inc., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2008 to YTD 2014 7
TargeGen, Inc., Pharmaceuticals & Healthcare, Deals Summary, 2008 to YTD 2014 8
TargeGen, Inc., Pharmaceuticals & Healthcare, Deal Details 9
Venture Financing 9
TargeGen Secures US$3.73 Million In Venture Financing 9
Partnerships 11
UCSD, Dana-Farber, Mayo Clinic And TargeGen Enter Into Co-Development Agreement For Myeloproliferative Disorders 11
Acquisition 13
Sanofi-Aventis Acquires TargeGen 13
TargeGen, Inc. - Key Competitors 17
Key Employees 18
Locations And Subsidiaries 19
Head Office 19
Appendix 20
Methodology 20
About GlobalData 20
Contact Us 20
Disclaimer 20
List Of Tables
List of Tables
TargeGen, Inc., Pharmaceuticals & Healthcare, Key Facts 1
TargeGen, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2008 to YTD 2014 1
TargeGen, Inc., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2008 to YTD 2014 1
TargeGen, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2008 to YTD 2014 4
TargeGen, Inc., Pharmaceuticals & Healthcare Deals By Type, 2008 to YTD 2014 5
TargeGen, Inc., Pharmaceuticals & Healthcare, Deals By Region, 2008 to YTD 2014 6
TargeGen, Inc., Deals By Therapy Area, 2008 to YTD 2014 7
TargeGen, Inc., Pharmaceuticals & Healthcare, Deals Summary, 2008 to YTD 2014 8
TargeGen Secures US$3.73 Million In Venture Financing 9
UCSD, Dana-Farber, Mayo Clinic And TargeGen Enter Into Co-Development Agreement For Myeloproliferative Disorders 11
Sanofi-Aventis Acquires TargeGen 13
TargeGen, Inc., Key Competitors 17
TargeGen, Inc., Key Employees 18
List Of Figures
List of Figures
TargeGen, Inc., Pharmaceuticals & Healthcare, Deals by Type, 2008 to YTD 2014 1
TargeGen, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2008 to YTD 2014 4
TargeGen, Inc., Pharmaceuticals & Healthcare, Deals by Type, 2008 to YTD 2014 5
TargeGen, Inc., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2008 to YTD 2014 7
PURCHASE OPTIONS
 
 
 

How can we help you?

Contact us at the Consulting WP office nearest to you or submit a business inquiry online.


  Contact
 

Subscribe to Our Newsletter